Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The Sigma non-opioid intracellular receptor 1, commonly known as the Sigma-1 receptor (SIGMAR1), is a unique ligand-operated molecular chaperone primarily localized at the mitochondria-associated endoplasmic reticulum membrane (MAM) [1, 2]. Unlike traditional cell-surface receptors, SIGMAR1 functions by stabilizing client proteins, such as the Inositol 1,4,5-trisphosphate receptor (IP3R), to facilitate essential calcium signaling between the ER and mitochondria [3, 5]. Under conditions of cellular stress or upon agonist binding, the receptor dissociates from its binding partner BiP/GRP78 and translocates to various cellular compartments, where it modulates the activity of diverse ion channels and G protein-coupled receptors [10, 14]. This regulatory versatility makes it a critical player in maintaining proteostasis, mitochondrial bioenergetics, and neurotransmission [5, 13]. SIGMAR1 has emerged as a high-priority therapeutic target for neurodegenerative and neuropsychiatric disorders, including Alzheimer’s disease, Amyotrophic Lateral Sclerosis (ALS), and major depression [3, 8, 10]. Loss-of-function mutations in the SIGMAR1 gene are directly linked to juvenile ALS and distal hereditary motor neuropathies [8, 10]. Pharmacological agonists, such as pridopidine and blarcamesine, are being investigated for their neuroprotective potential by restoring ER-mitochondrial crosstalk and reducing oxidative stress [3, 13]. Conversely, SIGMAR1 antagonists have shown efficacy in preclinical models for treating neuropathic pain and certain cancers, where they disrupt the receptor's pro-survival signaling in malignant cells [12, 14]. Despite its therapeutic promise, challenges remain regarding receptor selectivity and the systemic impact of its widespread expression in the human body [13, 15].
Functions as a ligand-regulated molecular chaperone that stabilizes Inositol 1,4,5-trisphosphate receptors (IP3R) at the mitochondria-associated ER membrane (MAM) to facilitate calcium signaling. It also modulates the conductance of voltage-gated ion channels and the trafficking of G protein-coupled receptors following translocation from the ER.
9 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Sigma non-opioid intracellular receptor 1 (Sigma-1 receptor) (SIGMAR1).